Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Metastatic renal cell carcinoma (mRCC) is a complex cancer requiring targeted therapies.
• Understanding the adverse event profiles of these treatments is crucial for patient management.
• Bleeding events and thrombocytopenia are known potential side effects of several mRCC drugs.

Purpose of the Study:

• To systematically review and illustrate the bleeding risks associated with targeted therapies used in mRCC treatment.
• To compare the incidence of bleeding events and thrombocytopenia across different targeted agents.
• To identify specific drugs with higher or lower bleeding risk profiles.

Main Methods:

• A systematic review of phase II, III, or IV clinical trials involving specific mRCC targeted therapies.
• Data collection included types of bleeding events, frequency, and incidence of thrombocytopenia.
• Searched ClinicalTrials.gov for serious bleeding adverse effects.
• Assessed trial quality using Jadad scoring.

Main Results:

• Bleeding event incidences ranged from 1% to 36%.
• Thrombocytopenia incidences ranged from 2% to 78%.
• Serious bleeding adverse events ranged from 1% to 7%.
• Bevacizumab exhibited the highest bleeding incidence, whereas axitinib demonstrated the lowest.

Conclusions:

• Targeted therapies for mRCC are associated with a spectrum of bleeding risks and thrombocytopenia.
• Bevacizumab is linked to a higher incidence of bleeding events compared to other agents reviewed.
• Axitinib appears to have a comparatively lower bleeding risk profile in mRCC treatment.
• All reviewed trials were of high quality, supporting the reliability of the findings.